Etoposide in combination with low-dose CAG (cytarabine, aclarubicin, G-CSF) for the treatment of relapsed or refractory acute myeloid leukemia: a multicenter, randomized control trial in southwest China.

Xi Zhang, Yunlong Li, Yanqi Zhang, Xinghua Chen, Cheng Zhang, Li Gao, Peiyan Kong, Yao Liu, Qin Wen, Yunjing Zeng, Qingyu Wang, Yi Su, Chunsen Wang, Sanbin Wang, Zhong Yuan, Lei Gao

Journal: Leukemia research 2013;37(6):657-64

PMID: 23537708

Full Text on Elsevier Science View on PubMed

Abstract

In a well-controlled multi-center randomized trial in southwestern China, 228 patients with refractory or relapsed AML were received a low-dose CAG regimen either with etoposide (E-CAG) or without etoposide (CAG). The complete remission (CR) rate, overall survival (OS) and toxicity were evaluated. Patients with E-CAG had a higher CR rate (71.1% vs. CAG 50.9%, P=0.0002). The tolerability appeared to be equivalent. Patients with CR who underwent allogenic hematopoietic stem cell transplantation (allo-HSCT) had a higher five-year OS over those without allo-HSCT (73.8% vs. 10.8%, P=0.000). The E-CAG regimen is expected to become a bridge between relapsed or refractory AML and allo-HSCT.

Address: Department of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, China.

DOI: 10.1016/j.leukres.2013.03.005

Link outs

Free resources

Medical:

https://medlineplus.gov/acutemyeloidleukemia.html

Other Literature Sources:

https://scite.ai/reports/23537708

Subscription / membership required

Full Text Sources:

MeSH Terms: Aclarubicin, Adolescent, Adult, Aged, Antineoplastic Agents, Phytogenic, Antineoplastic Combined Chemotherapy Protocols, China, Cytarabine, Dose-Response Relationship, Drug, Drug Resistance, Neoplasm, Etoposide, Female, Granulocyte Colony-Stimulating Factor, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Recurrence, Treatment Failure, Treatment Outcome, Young Adult